Erudio Healtherudio.com
Drug
Ceralasertib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying ceralasertib: VIOLETTE. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| VIOLETTE NCT03330847 · AstraZeneca | metastatic triple-negative breast cancer | Phase 2 | 24 | 6 | Focused | Nov 19, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LATIFY NCT05450692 · AstraZeneca DeepView → | advanced or metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| S2409 NCT06769126 · SWOG Cancer Research Network StandardView → | extensive stage small cell lung cancer | Phase 2 | Standard | View | |||